Abstract
Background: An increasing amount of evidence suggests an association between epilepsy and multiple somatic and psychiatric conditions, which is more significant than in the general population. Furthermore, a bidirectional association has been established between epilepsy and several conditions, notably depression and suicide, cerebrovascular disease, stroke, dementia and migraine, which is best explained by the presence of common underlying mechanisms and risk factors. Gaining knowledge about these common mechanisms can provide insight into new therapeutic targets, screening and preventive measures.
Methods: This review discusses several of the more significant somatic and psychiatric comorbidities of epilepsy, the mechanisms and direction of their association, as well as the implications of these comorbidities for treatment. Results: Somatic and psychiatric comorbidity in epilepsy have been investigated in several population-based studies using medical records databases and different survey methods. All show a significantly higher prevalence for a number of medical conditions in people with epilepsy (PWE) compared to the general population. Conclusion: The coexistence of different medical conditions with epilepsy carries important implications for the assessment of the burden of the disease and the outcome and management of these patients, as they often require long-term antiepileptic drug intake.Keywords: Comorbidities, somatic, psychiatric, epilepsy, risk factors, treatment.
Current Pharmaceutical Design
Title:Epilepsy, Comorbidities and Treatments
Volume: 23 Issue: 37
Author(s): Alla Guekht*
Affiliation:
- Russian National Research Medical University, Moscow,Russian Federation
Keywords: Comorbidities, somatic, psychiatric, epilepsy, risk factors, treatment.
Abstract: Background: An increasing amount of evidence suggests an association between epilepsy and multiple somatic and psychiatric conditions, which is more significant than in the general population. Furthermore, a bidirectional association has been established between epilepsy and several conditions, notably depression and suicide, cerebrovascular disease, stroke, dementia and migraine, which is best explained by the presence of common underlying mechanisms and risk factors. Gaining knowledge about these common mechanisms can provide insight into new therapeutic targets, screening and preventive measures.
Methods: This review discusses several of the more significant somatic and psychiatric comorbidities of epilepsy, the mechanisms and direction of their association, as well as the implications of these comorbidities for treatment. Results: Somatic and psychiatric comorbidity in epilepsy have been investigated in several population-based studies using medical records databases and different survey methods. All show a significantly higher prevalence for a number of medical conditions in people with epilepsy (PWE) compared to the general population. Conclusion: The coexistence of different medical conditions with epilepsy carries important implications for the assessment of the burden of the disease and the outcome and management of these patients, as they often require long-term antiepileptic drug intake.Export Options
About this article
Cite this article as:
Guekht Alla*, Epilepsy, Comorbidities and Treatments, Current Pharmaceutical Design 2017; 23 (37) . https://dx.doi.org/10.2174/1381612823666171009144400
DOI https://dx.doi.org/10.2174/1381612823666171009144400 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Activators and Inhibitors of the Ion Channel of the NMDA Receptor
Current Drug Targets Borna Disease Virus (BDV): Neuropharmacological Effects of a CNS Viral Infection
Current Neuropharmacology Effect of Nutrient Medium, Phytohormones and Elicitation Treatment on in-vitro Callus Culture of Bacopa monniera and Expression of Secondary Metabolites
The Natural Products Journal Regulation of Self-Reactive T Cells by Human Immunoglobulins- Implications for Multiple Sclerosis Therapy
Current Pharmaceutical Design Radiopharmaceuticals in Neurological and Psychiatric Disorders
Current Clinical Pharmacology A1 Receptors Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry On Chemical Structures with Potent Antiepileptic/Anticonvulsant Profile
Mini-Reviews in Medicinal Chemistry Spatio-Temporal Fluctuations of Neural Dynamics in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Current Phthalocyanines Delivery Systems in Photodynamic Therapy: An Updated Review
Current Medicinal Chemistry Small Molecule-induced Beta-cell Regeneration from Alternate Cell Sources
Current Tissue Engineering (Discontinued) Neurotrophin Receptor Signaling as a Therapeutic Target for Huntington's Disease
CNS & Neurological Disorders - Drug Targets Targeting of Low-Molecular Weight Drugs to Mammalian Mitochondria
Drug Design Reviews - Online (Discontinued) Expression and Function of Cytochrome P450 in Brain Drug Metabolism
Current Drug Metabolism A Genetic Dissection of Antipsychotic Induced Movement Disorders
Current Medicinal Chemistry Endocannabinoid System: A Multi-Facet Therapeutic Target
Current Clinical Pharmacology Towards a “Metabolic” Subtype of Major Depressive Disorder: Shared Pathophysiological Mechanisms May Contribute to Cognitive Dysfunction
CNS & Neurological Disorders - Drug Targets Pramipexole Tachyphylaxis and its Management in Bipolar Depression
Letters in Drug Design & Discovery Preface
Current Medical Imaging Development of 1, 3 Benzothiazol-2-yl Hydrazine Derivatives Containing Semicarbazone and Thioamide Pharmacophore as Anticonvulsants
Letters in Drug Design & Discovery